Cas:47281-61-8 6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline manufacturer & supplier

Chemical Name:6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline

CAS.NO:47281-61-8

Synonyms:1-(4-Nitro-phenyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin;6,7-dimethoxy-1-(4′-nitrophenyl)-1,2,3,4-tetrahydrioisoquinoline;1-p-Nitrophenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisochinolin;1-(4-nitrophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;6,7-Dimethoxy-1-(4-nitro-phenyl)-1,2,3,4-tetrahydro-isoquinoline

Molecular Formula:C₁₇H₁₈N₂O₄

Molecular Weight:314.33600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:76.31000

Exact Mass:314.12700

LogP:3.69910

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(4-Nitro-phenyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6,7-Dimethoxy-1-(4-nitro-phenyl)-1,2,3,4-tetrahydro-isoquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(4-nitrophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline Use and application,1-(4-Nitro-phenyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin technical grade,usp/ep/jp grade.

Related News: The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. 6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline manufacturer The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances. 6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline supplier On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. 6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 6,7-dimethoxy-1-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline factory The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions.